Cannara Biotech (LOVFF) Q3 2026 Earnings Report

The call presents a broadly positive operational and financial picture: double-digit revenue growth (16% QoQ), continued profitability (adjusted EBITDA up 11% and 21 consecutive positive quarters), strengthened market penetration (national share gains and record monthly shares in Ontario and Alberta), accelerated capacity expansion and strategic partnerships (Medican acquisition, Blue River technology, CAD 21M Curaleaf agreement). Notable near-term negatives include lower quarterly free cash flow and operating cash flow versus the prior year driven by higher expansion capex, a modest dip in gross margin from product mix, higher receivables and inventory, and competitive pressures in certain categories. On balance, the highlights — consistent profitability, expanding distribution and market share, accelerated capacity rollout, and strategic deals — outweigh the lowlights tied to timing, investment-driven cash flow effects, and category competition.

Guidance highlighted a demand‑driven, accelerated capacity build: Cannara now has >58,000 kg annualized capacity and expects to activate four additional grow zones by the end of fiscal 2027 to reach ~75,000 kg (with a runway to 100,000 kg), staging three room activations in Q2–Q3 and the final in Q4 after Valleyfield processing upgrades complete in December; new rooms typically take ~5–6 months to meaningfully hit retail. The company also starts the Curaleaf bulk supply agreement on August 1 (up to CAD 21 million over two years, with Curaleaf sponsoring pursuit of EU GMP, a ~1–2 year process once construction is finished), and is funding expansion from internal cash and credit (YTD infrastructure investment >CAD 10.5M, drew CAD 2M of a CAD 10M facility at a 4.83% rate) while maintaining liquidity (CAD 21.8M cash, current assets CAD 97.7M, working capital ~CAD 65.1M) and profitability (Q3 gross cannabis revenue CAD 44.1M, total net revenue CAD 31.8M, adjusted EBITDA CAD 8.5M or 27% margin, net income CAD 4.8M).